Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3700 - Long-term explerience in the management of adolescents and young adults with cancer referred to a regional tertiary center for multidisciplinary care


09 Oct 2016


Poster display


Marcos Melián Sosa


Annals of Oncology (2016) 27 (6): 474-482. 10.1093/annonc/mdw387


M. Melián Sosa, R. Díaz, E. Navarro, J.A. Mendez, M.E. Medina, A. Torres, E. García, D. Akhoundova, J. Aparicio

Author affiliations

  • Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES


Abstract 3700


Adolescents and Young Adults (AYA) with cancer constitute a heterogeneous group in which improvements in survival rates (OS) have not kept pace with those achieved in younger patients.


Retrospective review of AYA (15-29 years) patients with cancer, except leukemias, referred for multidisciplinary treatment (1992-2014). Baseline characteristics, pathological type and stage, 1st -line treatments and OS were reviewed. Differences between three age groups (15-19, 20-24, 25-29 years) assessed with Chi-square and log-rank tests. A p-value 


286 patients. Median age 23 years (15-29); 33.1% (15-19 years), 23.6% (20-24 years) and 43.3% (25-29 years). Tumour types (% in age-groups): Paediatric-bone tumours 15.7% (28.7-13.4-7.3), germ-cell tumours (both sexes) 15.5% (11.7-17.9-17.1), adult-type epithelial tumours 14.1% (6.4-10.4-22.0), Hodgkin lymphoma 12% (11.7-11.9-12.2), non-rhabdomyosarcoma soft-tissue tumours 9.5 % (4.3-10.4-13.0), glial-derived brain tumours 7.7% (9.6-7.5-6.5), paediatric-type brain tumours 7.7% (8.5-9.0-6.5), non-Hodgkin lymphoma 4.9% (5.3-6-4.1%), endocrine tumours 2.8% (3.2-1.5-3.3), paediatric-type solid tumours 2.1% (4.3-3.0-0.0), other bone tumours 2.1% (0-4.5.0-2.4), melanoma 2.1% (1.1-1.5-3.3), liver tumours 1.8% (1.1-1.5-2.4) and rhabdomyosarcoma 1.8% (4.3-1.5-0.0). Locally advanced or metastases: 43.7% (45.8-37.3-45.6). 1st-line treatment: 62.5% surgery, 73.7% chemotherapy and 32.5% radiotherapy; 2.1% included in clinical trials. Median follow-up: 110 months (6-314 months). 5 and 10-year OS: 64 and 57%. No differences between age-groups in treatment patterns and pathology, except in incidence of paediatric bone tumours and adult-type epithelial tumours. There was a trend for worse OS in the 25-29 age group; 5 and 10-year OS were 68 and 64%, 66 and 53% and 56 and 36%, respectively (p 0.06).


Patients in the 25-29 years-group fared worse than younger patients. More biologically aggressive presentations and a higher rate of adult-type epithelial neoplasms could justify these findings. Inclusion in clinical trials remains disappointingly low.

Clinical trial identification

Legal entity responsible for the study

Hospital Universitario La Fe




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings